2025
Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey
Brehm N, Biavasco F, Clausen J, Jung J, Maas-Bauer K, Wäsch R, Verbeek M, Nuernbergk C, Ihorst G, Seropian S, Finke J, Gowda L, Sidlik Muskatel R, Peffault de Latour R, Socie G, Wehr C, Michonneau D, Zeiser R. Teduglutide for treatment-refractory severe intestinal acute graft-versus-host disease - a multicenter survey. Bone Marrow Transplantation 2025, 60: 873-878. PMID: 40229535, PMCID: PMC12151853, DOI: 10.1038/s41409-025-02586-2.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide-2Non-relapse mortalityIntestinal acute graft-versus-host diseaseLevels of glucagon-like peptide-2Acute graft-versus-host diseaseGraft-versus-host diseaseMulticenter surveyAllogeneic hematopoietic cell transplantationRetrospective multicenter surveyHematopoietic cell transplantationFraction of patientsAlbumin serum levelsIntestinal stem cellsGVHD severitySR-aGVHDTeduglutide treatmentAcute GVHDAllo-HCTCell transplantationProspective trialsPreclinical dataSerum levelsTreated patientsRetrospective analysisFollow-upTSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Pineiro L, Gill S, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation And Cellular Therapy 2025, 31: s59-s60. DOI: 10.1016/j.jtct.2025.01.096.Peer-Reviewed Original ResearchRIC HCTReduced intensity conditioningHematopoietic cell transplantationRelapse-free survivalPost-HCTControl subjectsControl armDonor chimerismGrade II-IV acute graft-versus-host diseaseII-IV acute graft-versus-host diseaseT cell receptor-engineered T cellsAcute graft-versus-host diseasePhase 1 dose-escalation studyIncreased relapse-free survivalGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationNon-relapse deathPost-HCT MRDEngineered T cellsCytokine release syndromeData cut-offMonths post-HCTReducing relapse ratesYears post-HCTAssessment of efficacyOutcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian Follow-UpSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experience
2024
Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease
Maurya P, Liang J, Prior D, Ramachandran S, Deng Y, Krishnamurti L. Pre-Transplant Liver Fibrosis Predicts Poor Overall Survival Following Hematopoietic Stem Cell Transplantation for Sickle Cell Disease. Blood 2024, 144: 2302-2302. DOI: 10.1182/blood-2024-211601.Peer-Reviewed Original ResearchGraft-versus-host diseaseHematopoietic stem cell transplantationOutcome of hematopoietic stem cell transplantationVeno-occlusive diseaseChronic graft-versus-host diseaseCenter for International Blood and Marrow Transplant ResearchSickle cell diseaseEvent free survivalStem cell transplantationOverall survivalPresence of fibrosisPoor overall survivalThrombotic microangiopathyLiver fibrosisLiver biopsyFree survivalCell transplantationClinical trials of hematopoietic stem cell transplantationIncidence of acute graft-versus-host diseasePre-transplantTransfusional hemosiderosisAssociated with event free survivalAcute graft-versus-host diseaseGraft-versus-host disease prophylaxisPost-hematopoietic stem cell transplantationOncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice
Talvard-Balland N, Braun L, Dixon K, Zwick M, Engel H, Hartmann A, Duquesne S, Penter L, Andrieux G, Rindlisbacher L, Acerbis A, Ehmann J, Köllerer C, Ansuinelli M, Rettig A, Moschallski K, Apostolova P, Brummer T, Illert A, Schramm M, Cheng Y, Köttgen A, Duyster J, Menssen H, Ritz J, Blazar B, Boerries M, Graeff A, Sariipek N, van Galen P, Buescher J, Cabezas-Wallscheid N, Pahl H, Pearce E, Soiffer R, Wu C, Vago L, Becher B, Köhler N, Wertheimer T, Kuchroo V, Zeiser R. Oncogene induced TIM-3 ligand expression dictates susceptibility to anti-TIM-3 therapy in mice. Journal Of Clinical Investigation 2024, 134: e177460. PMID: 38916965, PMCID: PMC11324309, DOI: 10.1172/jci177460.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseAcute myeloid leukemiaPost-allo-HCTTim-3GVL effectLigand expressionGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationCD8+ T cellsEnhanced GVL effectIFN-g productionLow ligand expressionTim-3 ligandAnti-PD-1TIM-3 blockadeAnti-Tim-3Hematopoietic cell transplantationSurvival of miceCells of patientsAllo-HCTLeukemia relapseCell transplantationCause of deathMyeloid leukemiaT cellsTargeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment
Choe H, Nath R, Seropian S, Litzow M, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Abedin S, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco J, Jamieson K, Silverman M, van Besien K, Schuster M, Law A, Spross J, Li K, Nagl N, Vusirikala M, Nahar A, Desai A, Gyurkocza B. Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment. Transplantation And Cellular Therapy 2024, 30: s59-s60. DOI: 10.1016/j.jtct.2023.12.094.Peer-Reviewed Original ResearchHematopoietic cell transplantationAllogeneic hematopoietic cell transplantationTime to neutrophilCC armChronic GVHDDonor chimerismPlatelet engraftmentCell transplantationCumulative incidenceTherapeutic dosesCumulative incidence of grade III-IV acute graft-versus-host diseaseGrade III-IV acute graft-versus-host diseaseIII-IV acute graft-versus-host diseaseIncidence of grade III-IV acute graft-versus-host diseaseCumulative incidence of chronic GVHDCurative allogeneic hematopoietic cell transplantationDays post-hematopoietic cell transplantationAcute graft-versus-host diseaseControlled phase 3 studiesEradication of leukemic cellsGrade III-IV GvHDIncidence of chronic GVHDRadiation dose to marrowGraft-versus-host diseaseMedian time to neutrophilPD-1H/VISTA Agonism Inhibits Host Myeloid Antigen Presenting Cells That Suppresses Acute Graft-Versus-Host Disease without Losing Graft-Versus-Leukemia Effect
Hu Q, Fielder C, Huh W, Kassim A, Kim T. PD-1H/VISTA Agonism Inhibits Host Myeloid Antigen Presenting Cells That Suppresses Acute Graft-Versus-Host Disease without Losing Graft-Versus-Leukemia Effect. Transplantation And Cellular Therapy 2024, 30: s253. DOI: 10.1016/j.jtct.2023.12.336.Peer-Reviewed Original ResearchMyeloid antigen-presenting cellsHost antigen-presenting cellsAntigen-presenting cellsBone marrow transplantationMyeloid-derived suppressor cellsAllogeneic T cell proliferationAcute GVHDAcute GVHD symptomsGraft-versus-leukemiaPD-1HT cell proliferationHost miceT cellsBMT modelIsotype controlGraft-versus-leukemia (GVLSuppress acute graft-versus-host diseaseMHC-mismatched bone marrow transplantationAcute graft-versus-host diseaseT cell priming phaseGraft-versus-host diseaseMismatched bone marrow transplantationMyeloid antigen presenting cellsAcute GVHD treatmentDonor T cellsA phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Magenau J, Jaglowski S, Uberti J, Farag S, Riwes M, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang M, Burns L, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 2024, 143: 21-31. PMID: 37647633, PMCID: PMC10934299, DOI: 10.1182/blood.2023020250.Peer-Reviewed Original ResearchConceptsAcute graft-versus-host diseaseGraft-versus-host diseaseHematopoietic stem cell transplantationDose-limiting toxicityMUD hematopoietic stem cell transplantationGVHD-free survivalMultidose regimenMyeloablative conditioningHematologic malignanciesHuman leukocyte antigen-matched unrelated donorsPrevention of graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationCalcineurin inhibitor-based prophylaxisMatched ControlsDose-escalation phaseSingle-dose regimensStem cell transplantationPhase 2 trialSustained drug exposureAssociated with higher ratesDamage-associated molecular patternsExpansion cohortDouble-blindPlacebo-ControlledUnrelated donor
2018
Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models
Toubai T, Rossi C, Tawara I, Liu C, Zajac C, Oravecz-Wilson K, Peltier D, Sun Y, Fujiwara H, Riwes M, Henig I, Kim S, Suto M, Ishizawa K, Reddy P. Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models. Blood 2018, 132: 4529-4529. DOI: 10.1182/blood-2018-99-114634.Peer-Reviewed Original ResearchGraft-versus-host diseaseAcute graft-versus-host diseaseGVHD clinical scoresBone marrow transplantationT cell-independent mechanismDonor T cellsSR-GVHDHuman leukocyte antigenSplenic T cellsT cellsSteroid-refractoryClinical scoresAllo-HCTBone marrowMurine modelAbstract Acute graft-versus-host diseaseGraft-versus-host disease target organsSteroid-refractory graft-versus-host diseaseProgressive graft-versus-host diseaseRefractory graft-versus-host diseaseGut epithelial cellsMurine bone marrow transplantationHistopathological scoresWeight lossDays of DEX treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply